Dynavax Total Current Assets vs Capital Surpluse Analysis
DVAX Stock | USD 11.27 0.01 0.09% |
Dynavax Technologies financial indicator trend analysis is much more than just examining Dynavax Technologies latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dynavax Technologies is a good investment. Please check the relationship between Dynavax Technologies Total Current Assets and its Capital Surpluse accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.
Total Current Assets vs Capital Surpluse
Total Current Assets vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dynavax Technologies Total Current Assets account and Capital Surpluse. At this time, the significance of the direction appears to have strong relationship.
The correlation between Dynavax Technologies' Total Current Assets and Capital Surpluse is 0.73. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Dynavax Technologies, assuming nothing else is changed. The correlation between historical values of Dynavax Technologies' Total Current Assets and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Dynavax Technologies are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Total Current Assets i.e., Dynavax Technologies' Total Current Assets and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.73 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Capital Surpluse
Most indicators from Dynavax Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dynavax Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.At this time, Dynavax Technologies' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 95.41 in 2024, whereas Tax Provision is likely to drop slightly above 945.2 K in 2024.
2023 | 2024 (projected) | Interest Income | 26.8M | 28.1M | Non Recurring | 15.4M | 16.1M |
Dynavax Technologies fundamental ratios Correlations
Click cells to compare fundamentals
Dynavax Technologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dynavax Technologies fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 279.1M | 353.3M | 1.0B | 985.9M | 997.1M | 1.0B | |
Total Stockholder Equity | 8.3M | 58.7M | 222.4M | 581.0M | 622.1M | 653.2M | |
Retained Earnings | (1.2B) | (1.3B) | (1.2B) | (924.2M) | (930.6M) | (884.1M) | |
Other Assets | 3.6M | 3.8M | 368.9K | 3.5M | 3.2M | 3.0M | |
Common Stock Shares Outstanding | 72.0M | 100.8M | 133.0M | 150.8M | 128.7M | 135.2M | |
Liabilities And Stockholders Equity | 279.1M | 353.3M | 1.0B | 985.9M | 997.1M | 1.0B | |
Other Stockholder Equity | 1.2B | 1.4B | 1.4B | 1.5B | 1.6B | 1.6B | |
Total Liab | 270.8M | 294.6M | 816.9M | 404.8M | 375.0M | 393.8M | |
Other Current Liab | 43.8M | 32.6M | 201.4M | 143.2M | 24K | 22.8K | |
Total Current Liabilities | 53.0M | 77.4M | 556.4M | 150.1M | 62.2M | 58.2M | |
Accounts Payable | 9.3M | 3.3M | 2.6M | 3.2M | 5.2M | 3.1M | |
Cash | 39.9M | 32.1M | 436.2M | 202.0M | 150.3M | 157.8M | |
Short Term Investments | 111.2M | 133.0M | 109.8M | 422.4M | 592.0M | 621.6M | |
Other Current Assets | (8.9M) | (22.7M) | (131.8M) | 85.6M | 19.0M | 19.9M | |
Common Stock | 84K | 110K | 123K | 128K | 130K | 83.9K | |
Property Plant Equipment | 32.0M | 30.6M | 61.0M | 37.6M | 43.2M | 45.4M | |
Property Plant And Equipment Net | 32.0M | 57.2M | 61.0M | 63.3M | 61.6M | 64.7M | |
Net Debt | 176.6M | 185.8M | (178.8M) | 56.0M | 106.6M | 112.0M | |
Non Current Assets Total | 86.7M | 124.5M | 432.0M | 302.0M | 138.0M | 144.9M | |
Non Currrent Assets Other | 50.1M | 65.1M | 368.9M | 236.7M | 74.3M | 46.9M | |
Cash And Short Term Investments | 151.1M | 165.0M | 546.0M | 624.4M | 742.3M | 779.4M | |
Common Stock Total Equity | 84K | 110K | 123K | 128K | 147.2K | 85.0K | |
Non Current Liabilities Total | 217.7M | 217.2M | 260.5M | 254.8M | 312.8M | 328.5M | |
Property Plant And Equipment Gross | 62.3M | 57.2M | 61.0M | 63.3M | 93.4M | 98.1M | |
Total Current Assets | 192.4M | 228.7M | 607.3M | 683.8M | 859.1M | 902.1M | |
Accumulated Other Comprehensive Income | (2.4M) | 273K | (2.3M) | (5.4M) | (2.1M) | (2.2M) | |
Net Receivables | 8.9M | 22.7M | 131.8M | 147.5M | 44.5M | 46.8M | |
Other Liab | 1.3M | 2.6M | 5.7M | 384K | 345.6K | 328.3K | |
Good Will | 2.1M | 2.3M | 2.1M | 2.0M | 2.1M | 1.8M | |
Inventory | 41.3M | 63.7M | 61.3M | 59.4M | 53.3M | 56.0M | |
Short Long Term Debt Total | 216.4M | 217.8M | 257.4M | 258.0M | 256.9M | 148.6M | |
Long Term Debt | 178.6M | 179.8M | 220.5M | 221.6M | 222.7M | 233.8M | |
Net Tangible Assets | 3.7M | 56.4M | 220.2M | 579.0M | 665.9M | 699.2M | |
Retained Earnings Total Equity | (1.2B) | (1.3B) | (1.2B) | (924.2M) | (831.8M) | (873.4M) | |
Capital Surpluse | 1.2B | 1.4B | 1.4B | 1.5B | 1.7B | 1.1B | |
Non Current Liabilities Other | 39.1M | 37.4M | 5.7M | 33.2M | 74K | 70.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.Note that the Dynavax Technologies information on this page should be used as a complementary analysis to other Dynavax Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Dynavax Stock analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Dynavax Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dynavax Technologies. If investors know Dynavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dynavax Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share 0.07 | Revenue Per Share 1.826 | Quarterly Revenue Growth 0.082 | Return On Assets (0.01) |
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dynavax Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.